Crossmark

Clinical factors associated with delayed ischemic and non-ischemic adverse events in clazosentan therapy after aneurysmal subarachnoid hemorrhage: early insights from a multicenter prospective registry

Crossref DOI link: https://doi.org/10.1007/s10143-025-03646-3

Published Online: 2025-06-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sugiyama, Taku

Hokari, Masaaki

Shimbo, Daisuke

Uchino, Haruto

Shimoda, Yusuke

Okamoto, Michinari

Ito, Yasuhiro

Gekka, Masayuki

Saito, Hisayasu

Yamamoto, Taiji

Fujiwara, Yusuke

Fujimura, Miki
License Information

Text and Data Mining valid from 2025-06-05

Version of Record valid from 2025-06-05
More Information

Article History

Received: 24 March 2025

Revised: 26 May 2025

Accepted: 31 May 2025

First Online: 5 June 2025

Declarations

:

: This study was approved by the central Institutional Review Board (IRB) of Hokkaido University Hospital (No. 022–0137) and the IRBs of each participating institute.

: Informed consent was obtained from all individual participants included in this study.

: The authors affirm that human research participants provided informed consent for publication.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below